GENENTECH STOPS ENROLLING PATIENTS IN AVASTIN STUDY
Genentech has stopped enrolling ovarian cancer patients in a mid-stage clinical study of Avastin due to greater occurrences of gastrointestinal perforations than shown in previous studies of the drug.
The company discontinued enrollment in the Phase II trial after five out of 44 patients given Avastin showed signs of gastrointestinal perforations, a known possible risk of using the drug. The trial was expected to enroll 53 patients with ovarian cancer who had not responded to platinum-based chemotherapy. Patients already enrolled in the trial can choose to continue the treatment or drop out of the study.
The FDA approved the drug last year for advanced colon cancer, but Avastin is also being studied to treat prostate, kidney and pancreatic cancer.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May